No published half life for it turned up in the searches behind this entry. The Austrian label says a direct measurement of what the body does with the drug cannot be carried out at all, because the fragments in it are similar or identical to short pieces the body already makes, and the indirect figures were set from what the drug appears to do rather than from measuring it. That is the regulator's own document saying the drug cannot be measured directly in the body.
What it actually is
Cerebrolysin is not a single molecule and not a peptide in the sense the rest of this reference uses the word. It is an extract. One millilitre holds 215.2 mg of pig brain protein chopped up by enzymes, in water, with sodium hydroxide and water for injection the only other things in the ampoule. Because there is no one substance in there, there is no sequence for a laboratory report to confirm, and the American substance registry files it as structurally diverse, its term for a substance with no definable structure. It is also a real prescription medicine, which is unusual here: Austria has licensed it since March 1996, prescription and pharmacy only, for supportive treatment of cerebrovascular disorders in adults and patients over 65.
What it is supposed to do
The label's own account is that pieces of the mixture cross the blood brain barrier, the filter that keeps most things in the blood out of brain tissue, and that account is indirect rather than measured: animal experiments produced the same effects whether the substance went straight into the fluid spaces of the brain or into the body elsewhere, and the label calls that indirect evidence in its own words. The story that sells it is neurotrophic, the idea that the mixture imitates the brain's own growth factors. Part of the animal work behind that story has been withdrawn. Filtering PubMed to retracted publications and searching cerebrolysin returns ten records, and the seven opened for this entry are all mouse and rat work retracted between 2025 and 2026, with no reason given on the notices opened. No clinical result was found withdrawn, and no published reassessment of the mechanism since the retractions turned up in the searches behind this entry.
What people take it for
Inside the licence it is prescribed for supportive treatment of cerebrovascular disorders, in particular Alzheimer type and vascular dementia, deficits following a stroke, and head injury, in adults and patients over 65. Outside it, healthy adults buy it for thinking and memory, and that is the use with the least behind it. Two published studies of cognition in adults who did not have the disease turned up in the searches behind this entry: 48 healthy men given 10, 30 or 50 mL into a vein daily for 10 days in 1998, whose clearest effect came at the lowest volume and whose highest volume the authors read as showing signs of overdose, and healthy elderly control subjects given a single 30 mL dose by mouth in 2000, whose participant count could not be obtained. Every other trial here was in patients.
The dose question
What circulates
5 to 10 mL a day, under the skin or into a muscle
What was studied
10 to 50 mL a day into a vein, in patients
The Austrian label's table by condition, and the stroke and dementia trials behind it
Below the studied dose
The circulating amount runs at or below the bottom of every row of that table, its upper end of 10 mL landing exactly on the bottom of the dementia row. The reason it stops there looks mechanical rather than clinical, and that is a reading rather than something the label states: 5 mL is the most the label allows into a muscle, 10 mL the most allowed as a straight injection into a vein, and from 10 mL the label recommends a drip. There is a second gap in the route. Injection under the skin appears nowhere on the label, which lists muscle, vein and drip only, and a PubMed search for cerebrolysin and subcutaneous returned seven records, every one a rodent study or one that does not name a human population.
Reported because it is what people use. Nothing here recommends any amount.
How long it lasts
No published half life for it turned up in the searches behind this entry. The Austrian label says a direct measurement of what the body does with the drug cannot be carried out at all, because the fragments in it are similar or identical to short pieces the body already makes, and the indirect figures were set from what the drug appears to do rather than from measuring it. That is the regulator's own document saying the drug cannot be measured directly in the body.
Route studied
Into a vein, in patients, in hospital, at 10 to 50 mL a day, most of it as a slow drip. The label permits up to 5 mL into a muscle and up to 10 mL as a straight injection into a vein, and from 10 mL it recommends a drip given over about 15 to 60 minutes.
Route used
Injected under the skin or into a muscle, at home, from an ampoule.
How to check you have the right molecule
There is no molecular weight and no sequence to hold a laboratory report against, because this is an extract rather than a compound, which is why the American substance registry files it as structurally diverse. So the checks are on paperwork and wording. The first is the authorisation: Austria's number is 1-21380, granted 25 March 1996, and the holder is EVER Neuro Pharma GmbH of Unterach, Austria. The second is the route a seller names. The label lists injection into a muscle, injection into a vein and a slow drip, and the word for under the skin does not appear in it, so a seller describing injection under the skin is describing something the label does not cover. The third is that a licence somewhere in Europe is patchier than the shorthand suggests: Slovenia's central medicines database lists three Cerebrolysin entries held by three different importers, and all three carry a temporary permit to bring the medicine in for the treatment of an individual patient rather than a Slovenian marketing authorisation.
Two mistakes, and they stack. The first is reading the Austrian licence as covering the reason people buy it. The licence is real, and it is the most useful thing a seller could be handed, but it is for supportive treatment of cerebrovascular disorders in patients, given in a clinic and mostly by drip. Nothing in it speaks to a healthy adult injecting an ampoule under the skin for memory, and behind that use sit two studies, from 1998 and 2000. The second is arithmetic printed by the vendor guide itself. It glosses 5 to 10 mL a day as roughly 500 mg to 1,000 mg of the protein hydrolysate, when at the label's 215.2 mg per millilitre those volumes are 1,076 mg and 2,152 mg. The stated milligram figures are out by about a factor of two, in the direction that makes the dose sound smaller.
What is known about harm
The label rules the drug out in three situations: hypersensitivity to it, a seizure that will not stop, and severe kidney impairment. It warns that in epileptic conditions seizures may become more frequent, and among its very rare effects, meaning fewer than one person in ten thousand, it records isolated grand mal seizures, the kind that convulse the whole body, and allergic reactions up to a shock like state. Notice how many entries carry the phrase after too rapid administration: dizziness, palpitations or an irregular heartbeat, heat with sweating. The label's answer to several of its own adverse effects is to slow the drip, which is a hospital's answer. That someone injecting an ampoule at home does not have that option is a reading of the label rather than something the label says. Separately, Cochrane pooled 3 placebo controlled trials and 1,335 people, roughly half on saline, at 10 to 50 mL into a vein, and found non fatal serious adverse events at 2.39 times the placebo rate, range 1.10 to 5.23. That was the only pooled result in the review whose range stayed entirely above 1.